Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
January 6, 2016 9:26 AM ESTRoth Capital reiterated a Buy rating and $15.00 price target on Conatus Pharmaceuticals (NASDAQ: CNAT) following the company's reported three-month data from its double-blind, placebo-controlled Phase 2 trial in liver cirrhosis patients. The data indicated that there is a significant functional benefit for severe cirrhotic patients treated with emricasan.
Analyst Elemer Piros commented,... More
Conatus Pharmaceuticals (CNAT) Resumes Trading; Shares Up 10%
January 5, 2016 4:38 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month, double-blind, placebo-controlled stage... More
Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ET
January 5, 2016 4:11 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 4.35 PM ET
... More